Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline

Newsroom

Ferring Pharmaceuticals moves forward with early stage development of bacteriophage therapy for inflammatory bowel disease.

SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).


Click here to read more

See more Newsroom

Canada

Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 
Canada

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692

Contact